Greater Noida: Under the guidance of Uttar Pradesh Chief Minister Yogi Adityanath and on the initiative of Invest UP, the Yamuna Expressway Industrial Development Authority has issued a Letter of Intent (LoI) for 10 acres of land under the Medical Devices Park to Shukra Pharmaceuticals Limited.
On this occasion, CEO of Yamuna Expressway Authority Rakesh Kumar Singh, ACEO Shailendra Bhatia and representatives from Shukra Pharmaceuticals Limited —including Dr. Minakshi Late (Group Chief Executive Officer and Global Head), Gaurav Shokeen (Chief Operating Officer), Anil Kumar Verma (Vice President) and Kamini Bharti (Business Unit Head) —were present.
At the Medical Devices Park, Shukra Pharmaceuticals Limited will manufacture some of the world most advanced and life-saving medical technologies, helping position India at the forefront of global healthcare innovation. This state-of-the-art facility will Produce BNCT (Boron Neutron Capture Therapy), which is considered one of the most advanced treatment methods for patients suffering from complex cancer Conditions.
The plant will manufacture a wide range of radiology and imaging equipment, including CT scanners, MRI machines, PET scanners, X-ray systems and ultrasonography machines. In addition, anesthesia systems and respiratory care solutions required for ICU and operation theatres will also be developed.
The Medical Devices Park will also produce cardiovascular implants such as heart valves, stents and Left Ventricular Assist Devices (LVAD), which will support the treatment of patients with severe heart diseases. Special focus will also be placed on respiratory support products such as ventilators and oxygen concentrators.
A major highlight of this project will be the development of medical robotic systems, including soft-tissue surgical robots, orthopedic robotic systems (with implants), dental robotic systems (with implants) and neuro-spine robotic systems, which will promote greater precision and innovation in surgical Procedures.
In addition, the facility will manufacture in-vitro diagnostic (IVD) solutions such as point-of-care testing devices and advanced analyzers, enabling faster and more accurate diagnosis for patients. To strengthen medical education and reduce Patient risk, medical simulators will also be installed in the park for training doctors, nurses and paramedical Professionals, supporting skill development through advanced simulation technologies.
With the vision of collaboration between government and industry, this initiative represents an important step toward building a future where advanced medical technology is not seen as a luxury but as a fundamental human right—accessible, affordable and impactful for all.
This ambitious project highlights Shukra Pharmaceuticals commitment to advancing healthcare innovation, strengthening indigenous manufacturing, and making India a self-reliant global leader in medical technology. Through this facility more than 900 direct and 2,000 indirect jobs will be created across manufacturing, research and development (R&D), quality, regulatory, sales, marketing and allied Services.
With a capital investment (CAPEX) of ₹587 crore, this MedTech Park will Place special emphasis on local recruitment and skill development, ensuring inclusive growth and empowering the youth of Uttar Pradesh. By localizing advanced technologies, Shukra Pharmaceuticals will reduce dependence on imports and ensure affordable access to world-class medical devices, so that life-saving innovations can reach every Patient.
